Genzyme Corporation / Novazyme Pharmaceuticals Inc.
2001 · Acquisition/Merger · $138M · Complete
Announcement Sentiment
100
Strongly positive
$137.5M Genzyme stock plus up to $87.5M contingent on first two product approvals. Pompe disease ERT (NZ-1001); led to Myozyme. John Crowley/William Canfield platform.